anti-CD52 humanized antibodies (Abzena)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD52 humanized antibodies (Abzena)
Drug Alias Nameanti-CD52 antibody (Antitope)ANT-1034ANT-2034
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCAMPATH-1 antigen modulatorsImmunosuppressants
TargetsCAMPATH-1 antigen
Therapy Area/IndicationsMultiple SclerosisLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAntitope
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbzena LtdAntitope
Active IndicationsN/A
Inactive IndicationsMultiple SclerosisLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A